Search - tctmd.com

Displaying 141 - 160 of 766

Sort: Relevancy | Date

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

October 14, 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

October 14, 2020

October 2020 News Roundup

News Opinion CV Team Dispatch

October 2020 News Roundup

October 01, 2020

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

News Daily News

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Michael O'Riordan

September 18, 2020

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

News Conference News ESC 2020

More Bleeding, Death With Ticagrelor Over Clopidogrel in Elderly Post-MI Patients: SWEDEHEART

Yael L. Maxwell

September 08, 2020

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

August 10, 2020

Short DAPT Reduces Bleeding With No Increase in MACE: Meta-analysis

News Daily News

Short DAPT Reduces Bleeding With No Increase in MACE: Meta-analysis

Yael L. Maxwell

June 30, 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

News Conference News EuroPCR 2020

No Survival Benefit With Revascularization in Stable CAD, Meta-analysis Confirms

Michael O'Riordan

June 26, 2020

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

News Conference News TVT 2020

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

Yael L. Maxwell

June 26, 2020

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

June 01, 2020

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

News Daily News

Clopidogrel Holds Advantage in Older NTSE ACS Patients: POPular AGE Published

Michael O'Riordan

April 27, 2020

As COVID-19 Spreads, US Cath Labs Ponder Fibrinolytics for STEMI

News

As COVID-19 Spreads, US Cath Labs Ponder Fibrinolytics for STEMI

Michael O'Riordan

April 17, 2020

Aspirin Okay for Up to 30 Days

News Conference News ACC 2020

Aspirin Okay for Up to 30 Days in A-fib Patients After ACS or PCI: AUGUSTUS

April 03, 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

News Conference News ACC 2020

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

Yael L. Maxwell

March 28, 2020

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

News Daily News

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

March 27, 2020

Conversations in Cardiology: Uncovered Struts on OCT After 12 Years?

News Opinion Conversations in Cardiology

Conversations in Cardiology: Uncovered Struts on OCT After 12 Years?

March 27, 2020

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

News Daily News

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

March 16, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.